Management of Newly Diagnosed Glioblastoma: Guidelines Development, Value and Application

Overview

Journal J Neurooncol

Publisher Springer

Date 2009 May 12

PMID 19430879

Citations 17

Authors

Jeffrey J Olson

Camilo E Fadul

Daniel J Brat

Srinivasan Mukundan

Timothy C Ryken

Affiliations

Soon will be listed here.

Abstract

The movement to create guidelines for management of medical maladies has been gaining strength for quality, academic, financial and political purposes over the past two decades. This applies to neurological diseases, too. Evidence-based guidelines created in a multidisciplinary fashion using predetermined criteria for grading scientific data and translating this to similarly ranked recommendations is a valuable approach to meeting this goal. The following is a summary of the methods used for, and the results of, an evidence-based guideline for the management of newly diagnosed glioblastoma. In addition to outlining recommendations by discipline, it also addresses how concerns and conflicts were addressed in their development and provides comment on future directions in management of this situation that may improve outcome. It is important that clinicians directly experienced in patient management take the lead in creation of guidelines related to the diseases they deal with, as these clinicians are clearly the most suited to being able to arrive at a meaningful and useful product.

Citing Articles

Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.

Goodman A, Velazquez Vega J, Glenn C, Olson J J Neurooncol. 2022; 158(2):179-224.

PMID: 35648306 DOI: 10.1007/s11060-022-04005-8.

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas.

Guram K, Smith M, Ginader T, Bodeker K, Pelland D, Pennington E Pract Radiat Oncol. 2018; 9(1):16-23.

PMID: 30195927 PMC: 6487873. DOI: 10.1016/j.prro.2018.06.001.

Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter.

Mehrabian H, Lam W, Myrehaug S, Sahgal A, Stanisz G J Neurooncol. 2018; 139(1):97-106.

PMID: 29594656 DOI: 10.1007/s11060-018-2846-0.

Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy.

Mehrabian H, Myrehaug S, Soliman H, Sahgal A, Stanisz G Sci Rep. 2018; 8(1):2475.

PMID: 29410469 PMC: 5802834. DOI: 10.1038/s41598-018-20624-6.

SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017).

Martinez-Garcia M, Alvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X Clin Transl Oncol. 2017; 20(1):22-28.

PMID: 29086250 PMC: 5785619. DOI: 10.1007/s12094-017-1763-6.

References

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U . Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology. 2002; 44(5):371-81. DOI: 10.1007/s00234-001-0760-0. View

Amundsen P, Dugstad G, Syvertsen A . The reliability of computer tomography for the diagnosis and differential diagnosis of meningiomas, gliomas, and brain metastases. Acta Neurochir (Wien). 1978; 41(1-3):177-90. DOI: 10.1007/BF01809148. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Valtonen S, Timonen U, TOIVANEN P, Kalimo H, Kivipelto L, HEISKANEN O . Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 1997; 41(1):44-8; discussion 48-9. DOI: 10.1097/00006123-199707000-00011. View

Giannini C, Scheithauer B, Burger P, Christensen M, Wollan P, Sebo T . Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol. 1999; 58(1):46-53. DOI: 10.1097/00005072-199901000-00006. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Tentori L, Graziani G . Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res. 2005; 52(1):25-33. DOI: 10.1016/j.phrs.2005.02.010. View

Piedbois P, Buyse M . Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol. 2004; 22(19):3839-41. DOI: 10.1200/JCO.2004.06.924. View

10.

Deutsch M, Green S, Strike T, Burger P, Robertson J, Selker R . Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys. 1989; 16(6):1389-96. DOI: 10.1016/0360-3016(89)90939-5. View

11.

Simmons M, Lamborn K, Takahashi M, Chen P, Israel M, Berger M . Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001; 61(3):1122-8. View

12.

Brem S, Bierman P, Black P, Brem H, Chamberlain M, Chiocca E . Central nervous system cancers. J Natl Compr Canc Netw. 2008; 6(5):456-504. DOI: 10.6004/jnccn.2008.0037. View

13.

Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D . Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006; 24(18):2707-14. DOI: 10.1200/JCO.2005.04.3414. View

14.

Brandes A, Vastola F, Basso U, Berti F, Pinna G, Rotilio A . A prospective study on glioblastoma in the elderly. Cancer. 2003; 97(3):657-62. DOI: 10.1002/cncr.11097. View

15.

Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H . Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5):392-401. DOI: 10.1016/S1470-2045(06)70665-9. View

16.

Walker M, Green S, Byar D, ALEXANDER Jr E, Batzdorf U, Brooks W . Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23):1323-9. DOI: 10.1056/NEJM198012043032303. View

17.

Levin V, Wara W, Davis R, Vestnys P, Resser K, Yatsko K . Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg. 1985; 63(2):218-23. DOI: 10.3171/jns.1985.63.2.0218. View

18.

Prayson R . Cell proliferation and tumors of the central nervous system, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol. 2002; 61(8):663-72. DOI: 10.1093/jnen/61.8.663. View

19.

Ford J, Stenning S, Boote D, Counsell R, Falk S, Flavin A . A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol). 1997; 9(1):20-4. DOI: 10.1016/s0936-6555(97)80053-2. View

20.

Mukundan S, Holder C, Olson J . Neuroradiological assessment of newly diagnosed glioblastoma. J Neurooncol. 2008; 89(3):259-69. DOI: 10.1007/s11060-008-9616-3. View